Search results
Genomic tools
- Avida Biomed develops genomic tools to reveal DNA alterations with unprecedented accuracy for clinical and research use. It offers molecular diagnostics through genomic tool innovation and integration.
People also ask
What is Avida BioMed?
What will Agilent do with Avida BioMed?
Why do scientists use Avida for research?
What is Avida ED?
Mass spectrometry, chromatography, spectroscopy, software, dissolution, sample handling and vacuum technologies courses. Live or on-demand webinars on product introductions, applications and software enhancements. Worldwide trade shows, conferences, local seminars and user group meetings.
- Agilent Announces Acquisition of Avida Biomed, Developer of ...
Avida Biomed’s technology will enable scientists working in...
- Agilent Announces Acquisition of Avida Biomed, Developer of ...
Jan 4, 2023 · Avida Biomed’s technology will enable scientists working in precision medicine to develop new approaches for a variety of applications including biomarker discovery, patient selection for clinical trials, diagnosis and prognosis, therapy selection, and disease recurrence.
Jan 4, 2023 · Avida Biomed’s technology will enable scientists working in precision medicine to develop new approaches for a variety of applications including biomarker discovery, patient selection for...
Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.
Jan 4, 2023 · Agilent Technologies announced the acquisition of Avida Biomed, an early stage life sciences company, on Jan. 4, 2022. This acquisition grants Agilent access to Avida’s high-performance enrichment workflows, which are designed to enable clinical researchers to use next-generation sequencing (NGS) approaches for studying cancer.
Jan 5, 2023 · Avida Biomed’s innovative genomics tools enable simultaneous genomic and DNA methylation profiling from a single sample without compromising sensitivity or specificity. The company’s streamlined assay protocol, which also includes library preparation, can be completed in a single shift enabling fast turnaround of assay results.
Jan 6, 2023 · Agilent Technologies Inc. (NYSE: A) announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.